A Pilot Study of the Feasibility and Accuracy of the TrueVie CGM System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

16 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-04

Study Completion Date

2022-06-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the investigation is to obtain sufficient preliminary information about the performance of the TrueVie Continuous Glucose Monitoring (CGM) device to identify any need for any design modifications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial

NCT05806554

Diabetes Mellitus

COMPLETED

PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor

NCT02154126

Diabetes Mellitus

COMPLETED NA

Evaluation of the Accuracy of an Implanted Glucose Sensor

NCT02647905

Diabetes Mellitus

COMPLETED NA

PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm

NCT03251079

Diabetes Mellitus Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

COMPLETED NA

Continuous Glucose Monitoring in Patients With Type 2 Diabetes

NCT00529815

Diabetes Mellitus Type 2

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After being informed about the study and potential risks, all participants giving written informed consent will be screened for participation. Qualifying participants will insert CGM sensors and come to 3 clinic visits at the beginning, middle and end of the 15 days intended sensor life. At the clinic visits participants are served two meals and perform a brief period of exercise of moderate intensity while blood samples are drawn according to a planned schedule timed to coincide with the TrueVie measurements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Continuous Glucose Monitoring

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

With oral ascorbic acid

1 g ascorbic acid orally

Continuous glucose monitoring device

Intervention Type DEVICE

Continuous glucose monitoring device

Laboratory plasma glucose concentration determination

Intervention Type OTHER

Laboratory plasma glucose concentration determination

Without oral ascorbic acid

No oral ascorbic acid is taken

Continuous glucose monitoring device

Intervention Type DEVICE

Continuous glucose monitoring device

Laboratory plasma glucose concentration determination

Intervention Type OTHER

Laboratory plasma glucose concentration determination

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Continuous glucose monitoring device

Intervention Type DEVICE

Laboratory plasma glucose concentration determination

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1 Type 1 diabetes mellitus 2. Must be and have been in stable treatment regimen for at least 3 months with a multiple daily insulin dosing regimens or Continuous Subcutaneous Insulin Infusion (CSII), irrespective of delivery device(s).

3\. Must have normal exercise tolerance.

Exclusion Criteria

1. Skin adhesive tolerance issues in the area of sensor placement
2. HbA1c \> 9%.
3. Insulin meal dosing based on fixed dose regimens.
4. Absence of established corrective factor for high glucose.
5. Hematocrit below 10% under the lower limit of the normal range.
6. Body mass index \< 20 kg/m2.
7. Inadequate intravenous access on arms.
8. Absence of moderate exercise tolerance per history
9. Pregnancy, planned pregnancy within the study period, or unwillingness to use reliable contraception during the study period.
10. Planned MRI, CT scan or diathermic procedure for the duration of the study.
11. Any medical history of malignant melanoma or breast cancer.
12. Medical history of any other cancers within the last five years except adequately treated basal cell or squamous carcinoma of the skin, or cervical carcinoma in-situ.
13. History of alcohol or drug abuse within the last year.
14. Any condition that in the opinion of the investigator may interfere successful completion of study procedures.
15. Participation in other clinical trials involving receipt of investigational drug that cannot be disclosed within the last 30 days.
16. Inability or unwillingness to conform to the required protocol procedures including giving informed consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No